Acacia Research Corp., of Newport Beach, Calif., named Michael Tognotti director of sales for CustomArray products in North America.

Angiotech Pharmaceuticals Inc., of Vancouver, British Columbia, nominated Glen Nelson tp its board.

Aurora Discovery, of San Diego, appointed Charles Powell vice president of sales and marketing.

Avitar Inc., of Canton, Mass., appointed Richard Anderson vice president of research and development.

Bio-America Inc., of Toronto, appointed Thomas Stevens president.

BioCryst Pharmaceuticals Inc., of Birmingham, Ala., appointed John Higgins to its board.

Biolase Technology Inc., of San Clemente, Calif., nominated Robert Anderton to its board.

C.E. Unterberg, Towbin in New York appointed Mark Green managing director in Israel.

Cadus Corp., of New York, elected David Blitz acting president and CEO.

Chromatin Inc., of Chicago, appointed Michael Pauly chief scientific officer.

CMC Biopharmaceuticals A/S, of Copenhagen, Denmark, appointed Richard Hart head of sales and marketing.

Concurrent Pharmaceuticals Inc., of Fort Washington, Pa., appointed Jeffrey Hatfield CEO.

Cryptome Pharmaceuticals Ltd., of Melbourne, Australia, appointed Paul Cossum a scientific consultant for drug development and regulatory affairs.

Depomed Inc., of Menlo Park, Calif., nominated Craig Smith and Gerald Proehl to its board.

Dyadic International Inc., of Jupiter, Fla., appointed Gerald Fink to its scientific advisory board.

GlobeImmune Inc., of Aurora, Colo., appointed Teresa Brentnall, Edgar Engleman, Edward Mocarski, Alan Venook and Bruce Walker to its scientific advisory board.

InfaCare Pharmaceutical Corp., of Neptune, N.J., appointed John Post chief operating officer.

Ingenium Research Inc., of Cary, N.C., appointed Joshua Baker president and CEO.

InKine Pharmaceutical Inc., of Blue Bell, Pa., appointed Robyn Karlstadt vice president of clinical operations.

Integrated Genomics Inc., of Chicago, appointed Katherine Andrews-Cramer director of business development, and Dave Oehler director of marketing and sales.

Inyx Inc., of New York, appointed Joseph Rotmil to its board.

Kemia Inc., of San Diego, appointed Richard Canote vice president of finance.

MorphoSys AG, of Martinsried, Germany, appointed Metin Colpan to its supervisory board.

Nabi Biopharmaceuticals Inc., of Boca Raton, Fla., appointed Richard Clark senior vice president of administration and chief administrative officer, and Thomas McLain chairman.

PediaMed Pharmaceuticals Inc., of Florence, Ky., appointed Jon Bruss vice president of clinical/medical/regulatory and chief medical officer.

Peninsula Pharmaceuticals Inc., of Alameda, Calif., appointed Keith Katkin vice president of commercial development.

Piper Jaffray & Co. in New York appointed Raj Denhoy vice president and senior research analyst in health care.

Raven Biotechnologies Inc., of South San Francisco, said its President and CEO Jennie Mather was elected to the BayBio board.

Scandinavian Life Science Venture in Copenhagen, Denmark, appointed Rigele Abilock senior investment director.

Sontra Medical Corp., of Franklin, Mass., appointed Gerard Puorro and Brian Sullivan to its board.

St. Francis Medical Technologies Inc., of Alameda, Calif., appointed Kevin Sidow president and CEO.

The Immune Response Corp., of Carlsbad, Calif., appointed David Mitchell executive director of regulatory affairs.

Valera Pharmaceuticals, of Cranbury, N.J., appointed Pete Perron vice president of sales.

VaxGen Inc., of Brisbane, Calif., named James Cunha chief financial officer.